Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday_老虎社区_美港股上老虎

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday

Motley Fool2021-09-29

Investors seem increasingly jittery about the future prospects for COVID-19 vaccines. Key Points Pfizer, BioNTech SE, and Novavax had some good news Tuesday. Vaccine stocks are falling, though, ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

101

Tanyl
·2021-09-29
My PFE option price reduce so much
回复
2
举报
关耳火丙光军
·2021-09-29
Good
回复
2
举报
PBL170
·2021-09-29
Like pls
回复
5
举报
Zyer
·2021-09-29
🚀
回复
2
举报
ZhiLing
·2021-09-29
ok
回复
3
举报
收起
- Trader0505:
  Ok
  2021-09-29
  回复
  举报
- Kc48:
  Like
  2021-09-29
  回复
  举报
Lemontart
·2021-09-29
Oh dear
回复
2
举报
themonkey
·2021-09-29
[微笑] [微笑] [微笑]
回复
2
举报
IZLIN
·2021-09-29
@Sagi08 @Meow17 @simplydkam[Surprised]
回复
4
举报
收起
- Sagi08:
  Ok
  2021-09-30
  回复
  举报
Geoz88
·2021-09-29
Like pls
回复
3
举报
YTRT
·2021-09-29
Thanks
回复
3
举报
BSBGS
·2021-09-29
Ok
回复
2
举报
收起
- 杰森杰森OvO:
  👍🏻
  2021-09-29
  回复
  举报
ElvisLHS
·2021-09-29
Read...pls like. Thanks in advance
回复
3
举报
收起
- DMC8:
  Ok
  2021-09-29
  回复
  举报
- RonnieO:
  Ok
  2021-09-29
  回复
  举报
- Geoz88:
  OK
  2021-09-29
  回复
  举报
SillyBear
·2021-09-29
Like please thanks
回复
2
举报
收起
- Juneriq:
  done
  2021-09-29
  回复
  举报
Butt3rc00ki3
·2021-09-29
Like
回复
4
举报
收起
- SillyBear:
  liked
  2021-09-29
  回复
  举报
- Mousey:
  Ok
  2021-09-29
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-29 08:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111572816","market":"us","top_or_hot":-1,"title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday","media":"Motley Fool","content":"<div>\nInvestors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, ...\n\n<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 08:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nInvestors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, ...\n\n<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","article_id":"1111572816","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","pubTimestamp":1632875079,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"translate_title":"为什么辉瑞、生物技术公司、莫德纳和诺瓦瓦克斯医药的股票周二下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9},"content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":865089471,"gmtCreate":1632923858620,"gmtModify":1632923874861,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"4087109808120260","idStr":"4087109808120260"},"htmlText":"My PFE option price reduce so much","listText":"My PFE option price reduce so much","text":"My PFE option price reduce so much","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/865089471","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862625113,"gmtCreate":1632876941087,"gmtModify":1632876941087,"author":{"id":"3582251063635557","authorId":"3582251063635557","name":"关耳火丙光军","avatar":"https://static.tigerbbs.com/7297dbb98183fa4daf629f4a49f6de07","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3582251063635557","idStr":"3582251063635557"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862625113","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862626555,"gmtCreate":1632876841697,"gmtModify":1632876841807,"author":{"id":"4087190594214920","authorId":"4087190594214920","name":"PBL170","avatar":"https://static.tigerbbs.com/8ef4f93ba3e261ac276aef28c4467365","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"4087190594214920","idStr":"4087190594214920"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862626555","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862629969,"gmtCreate":1632876519465,"gmtModify":1632876519465,"author":{"id":"3571640102147877","authorId":"3571640102147877","name":"Zyer","avatar":"https://static.tigerbbs.com/9eeca265fde5dd09236bfc86f9855657","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3571640102147877","idStr":"3571640102147877"},"htmlText":"🚀","listText":"🚀","text":"🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862629969","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862664359,"gmtCreate":1632876345575,"gmtModify":1632876345767,"author":{"id":"3557823792637532","authorId":"3557823792637532","name":"ZhiLing","avatar":"https://static.tigerbbs.com/40d052b9f7db59b50f72a3cbcbc99234","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3557823792637532","idStr":"3557823792637532"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/862664359","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6032033,"gmtCreate":1632877289283,"gmtModify":1634782918156,"authorId":3573216396035636,"author":{"id":3573216396035636,"idStr":"3573216396035636","authorId":3573216396035636,"name":"Trader0505","avatar":"https://static.tigerbbs.com/c50c5243fd8dd1cf060cabef7bcbb550","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862664359,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6032144,"gmtCreate":1632877754001,"gmtModify":1634782907571,"authorId":3582943967323128,"author":{"id":3582943967323128,"idStr":"3582943967323128","authorId":3582943967323128,"name":"Kc48","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862664359,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"CN"},{"id":862666377,"gmtCreate":1632876223234,"gmtModify":1632876223234,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"4087299128031090","idStr":"4087299128031090"},"htmlText":"Oh dear","listText":"Oh dear","text":"Oh dear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862666377","repostId":1111572816,"repostType":2,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862668675,"gmtCreate":1632876191858,"gmtModify":1632876191966,"author":{"id":"3573986430688942","authorId":"3573986430688942","name":"themonkey","avatar":"https://static.tigerbbs.com/573a67d390101884216129f5c49fe8a0","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3573986430688942","idStr":"3573986430688942"},"htmlText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","listText":"[微笑]&nbsp;[微笑]&nbsp;[微笑]&nbsp;","text":"[微笑] [微笑] [微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862668675","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862685055,"gmtCreate":1632875762478,"gmtModify":1632875762634,"author":{"id":"3581848609787274","authorId":"3581848609787274","name":"IZLIN","avatar":"https://static.tigerbbs.com/f2241963762942310c858a3aae49c0d1","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581848609787274","idStr":"3581848609787274"},"htmlText":"<a href=\"https://laohu8.com/U/3582026494482473\">@Sagi08</a><a href=\"https://laohu8.com/U/3581561113691319\">@Meow17</a><a href=\"https://laohu8.com/U/3582502706085184\">@simplydkam</a>[Surprised]&nbsp;","listText":"<a href=\"https://laohu8.com/U/3582026494482473\">@Sagi08</a><a href=\"https://laohu8.com/U/3581561113691319\">@Meow17</a><a href=\"https://laohu8.com/U/3582502706085184\">@simplydkam</a>[Surprised]&nbsp;","text":"@Sagi08@Meow17@simplydkam[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862685055","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6042725,"gmtCreate":1632959711154,"gmtModify":1634726226639,"authorId":3582026494482473,"author":{"id":3582026494482473,"idStr":"3582026494482473","authorId":3582026494482473,"name":"Sagi08","avatar":"https://static.tigerbbs.com/04a6ca80d31900bae8ec95b23446e79d","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862685055,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":862688626,"gmtCreate":1632875624591,"gmtModify":1632875624733,"author":{"id":"3579002978614578","authorId":"3579002978614578","name":"Geoz88","avatar":"https://static.tigerbbs.com/40716588ae7919100620a5b5a9c48cac","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3579002978614578","idStr":"3579002978614578"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862688626","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862689594,"gmtCreate":1632875438139,"gmtModify":1632875438139,"author":{"id":"4088994282428880","authorId":"4088994282428880","name":"YTRT","avatar":"https://static.tigerbbs.com/344b95c303c752be1a1e529b4f91ae17","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4088994282428880","idStr":"4088994282428880"},"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862689594","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":862617434,"gmtCreate":1632875349692,"gmtModify":1632875349692,"author":{"id":"4089378841570750","authorId":"4089378841570750","name":"BSBGS","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4089378841570750","idStr":"4089378841570750"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862617434","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6031493,"gmtCreate":1632875515282,"gmtModify":1634782970157,"authorId":4088596505254670,"author":{"id":4088596505254670,"idStr":"4088596505254670","authorId":4088596505254670,"name":"杰森杰森OvO","avatar":"https://static.tigerbbs.com/8dd96217e20c4a5496797a3224aba559","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862617434,"type":1,"supId":0,"prevId":0,"content":"👍🏻","text":"👍🏻","html":"👍🏻"}],"langContent":"CN"},{"id":862614710,"gmtCreate":1632875322259,"gmtModify":1632875322341,"author":{"id":"3582789589641542","authorId":"3582789589641542","name":"ElvisLHS","avatar":"https://static.tigerbbs.com/6fc810548fb80fd7014ebbdf5203e9ba","vip":1,"crmLevel":8,"crmLevelSwitch":0,"authorIdStr":"3582789589641542","idStr":"3582789589641542"},"htmlText":"Read...pls like. Thanks in advance&nbsp;","listText":"Read...pls like. Thanks in advance&nbsp;","text":"Read...pls like. Thanks in advance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/862614710","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6031488,"gmtCreate":1632875505885,"gmtModify":1634782970700,"authorId":3579992296424941,"author":{"id":3579992296424941,"idStr":"3579992296424941","authorId":3579992296424941,"name":"DMC8","avatar":"https://static.tigerbbs.com/65aa8f5f6299558ce2ab36482793f750","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862614710,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6031491,"gmtCreate":1632875510915,"gmtModify":1634782970374,"authorId":4088850777374920,"author":{"id":4088850777374920,"idStr":"4088850777374920","authorId":4088850777374920,"name":"RonnieO","avatar":"https://static.tigerbbs.com/1292a5981b699a40c70f37718afa2985","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862614710,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6031525,"gmtCreate":1632875633484,"gmtModify":1634782966987,"authorId":3579002978614578,"author":{"id":3579002978614578,"idStr":"3579002978614578","authorId":3579002978614578,"name":"Geoz88","avatar":"https://static.tigerbbs.com/40716588ae7919100620a5b5a9c48cac","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862614710,"type":1,"supId":6031491,"prevId":0,"content":"OK","text":"OK","html":"OK"}],"langContent":"CN"},{"id":862614500,"gmtCreate":1632875312953,"gmtModify":1632875313075,"author":{"id":"3574377591884909","authorId":"3574377591884909","name":"SillyBear","avatar":"https://static.tigerbbs.com/436cb9ef08189add55c76eed14c11620","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3574377591884909","idStr":"3574377591884909"},"htmlText":"Like please thanks","listText":"Like please thanks","text":"Like please thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/862614500","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6031474,"gmtCreate":1632875460711,"gmtModify":1634782972007,"authorId":3566969992567848,"author":{"id":3566969992567848,"idStr":"3566969992567848","authorId":3566969992567848,"name":"Juneriq","avatar":"https://static.tigerbbs.com/2ddc6553edddfa241ccd2e6cf2419f1f","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862614500,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"CN"},{"id":862615141,"gmtCreate":1632875220223,"gmtModify":1632875220374,"author":{"id":"3581548481060535","authorId":"3581548481060535","name":"Butt3rc00ki3","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3581548481060535","idStr":"3581548481060535"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/862615141","repostId":1111572816,"repostType":4,"repost":{"id":"1111572816","kind":"news","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=zh_CN&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":" <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday<blockquote>为什么辉瑞、BioNTech、Moderna和Novavax股价周二下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-09-29 08:24\n\n</h4>\n</header>\n<article>\n <a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines. Key <a href=\"https://laohu8.com/S/PCOM\">Points</a><blockquote><a href=\"https://laohu8.com/S/ISBC\">投资者</a>似乎对新冠肺炎疫苗的未来前景越来越紧张。钥匙<a href=\"https://laohu8.com/S/PCOM\">点数</a></blockquote> <ul> <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li> <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li> <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li> </ul> What happened<blockquote><ul><li><a href=\"https://laohu8.com/S/PFE\">辉瑞</a>,<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>，和<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>周二有一些好消息。</li><li>不过，疫苗库存正在下跌，可能是因为未来疫苗需求的不确定性。</li><li>冠状病毒变种仍有可能推动对COVID-19疫苗的持续需求。</li></ul>发生了什么</blockquote> This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.<blockquote>对于领先的COVID-19疫苗制造商的股票来说，这并不是一个好的一周。周一几只股票下跌。周二继续下跌。</blockquote> Shares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.<blockquote>本公司之股份辉瑞（纽约证券交易所股票代码：PFE）截至上午11:27下跌1.6%。BioNTech（纳斯达克：BNTX）股价下跌9.4%。现代（纳斯达克股票代码：MRNA）股价下跌6.2%。Novavax（纳斯达克：NVAX）的跌幅尤其大，其股价下跌了11.6%。</blockquote> The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.<blockquote>尽管其中一些疫苗股有一些好消息，但这些疫苗股还是下跌了。辉瑞和BioNTech向美国提交了初步数据。美国食品药品监督管理局对12岁至5岁儿童的新冠肺炎疫苗进行了后期研究。印度监管机构还允许印度血清研究所开始招募7至11岁的儿童参加评估Novavax COVID-19疫苗的临床试验。</blockquote> So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.<blockquote>那么为什么周二股市下跌呢？这可能是因为投资者对新冠疫苗销售前景越来越焦虑。辉瑞和Moderna的首席执行官最近预测，疫情可能会在2022年结束。</blockquote> Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.<blockquote>此外，辉瑞公司周一宣布，它已开始测试一种药丸，该药丸可用于在接触另一名COVID-19患者后预防感染。如果辉瑞的口服药物或类似的抗病毒疗法可用，可能会降低人们寻求疫苗接种的动力。</blockquote> So what<blockquote>那又怎样</blockquote> Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.<blockquote>投资者绝对应该展望未来来评估疫苗股的前景。2023年及以后，COVID-19疫苗销售是否会像现在一样强劲还存在不确定性。</blockquote> It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.<blockquote>毫不奇怪，辉瑞股价的跌幅没有BioNTech、Moderna或Novavax的股价那么大。这家大型制药商并不像BioNTech和Moderna那样完全依赖其COVID-19疫苗，Novavax可能很快就会如此。</blockquote> However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.<blockquote>然而，新出现的冠状病毒变种仍有可能导致未来几年对新冠肺炎疫苗的需求保持强劲。周二的抛售可能是没有根据的。</blockquote> Now what<blockquote>现在怎么办</blockquote> Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.<blockquote>这些股票中的每一只都有关键催化剂。辉瑞和BioNTech希望尽快向FDA申请其新冠肺炎疫苗在幼儿免疫中的紧急使用授权。Moderna正在等待加强剂量的决定。Novavax希望其COVID-19疫苗获得世界卫生组织的紧急使用清单，并计划在多个国家申请EUA。</blockquote> As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.<blockquote>不过，只要COVID-19疫苗未来需求的不确定性持续存在，所有这些股票都将持续波动。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1,"symbols_score_info":{"NVAX":0.9,"PFE":0.9,"BNTX":0.9,"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6031418,"gmtCreate":1632875321361,"gmtModify":1634782977438,"authorId":3574377591884909,"author":{"id":3574377591884909,"idStr":"3574377591884909","authorId":3574377591884909,"name":"SillyBear","avatar":"https://static.tigerbbs.com/436cb9ef08189add55c76eed14c11620","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862615141,"type":1,"supId":0,"prevId":0,"content":"liked","text":"liked","html":"liked"},{"id":6031428,"gmtCreate":1632875341459,"gmtModify":1634782976456,"authorId":3582013756437525,"author":{"id":3582013756437525,"idStr":"3582013756437525","authorId":3582013756437525,"name":"Mousey","avatar":"https://static.tigerbbs.com/830131bc3b204bdb28fb53b87586f968","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":862615141,"type":1,"supId":6031418,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":101,"commentSize":14,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}